Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide + dapagliflozin
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Semaglutide + dapagliflozin is a combination therapy of two pharmaceutical agents used primarily for the management of type 2 diabetes mellitus. Semaglutide is a glucagon-like peptide 1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to improved glycemic control and weight loss. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces renal glucose reabsorption in the proximal tubule, promoting urinary glucose excretion and lowering blood sugar levels. The combination has demonstrated superior efficacy in improving glycemic control and metabolic parameters compared to monotherapy with either agent[1][2]. Both drugs are also associated with cardiovascular and renal benefits.
- Brand names
- EdistrideQternQternmetXigduo
- Other names
- REVERT-PREDIABETES interventionsemaglutide and dapagliflozin
02
Targets
GLP1R (GLP-1R)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on semaglutide + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide + dapagliflozin.